LinkedIn Profile

Access Vigilant Biosciences historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:vigilantbiosciences 9016939 Dec 3rd, 2020 12:00AM Vigilant Biosciences, Inc. 789 18.00 Open Biotechnology Dec 3rd, 2020 03:17PM Dec 3rd, 2020 03:17PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Dec 2nd, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Dec 2nd, 2020 05:05PM Dec 2nd, 2020 05:05PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Dec 1st, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Dec 1st, 2020 03:39PM Dec 1st, 2020 03:39PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 30th, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 29th, 2020 09:36PM Nov 30th, 2020 06:35PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 28th, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 28th, 2020 05:10PM Nov 28th, 2020 05:10PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 27th, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 27th, 2020 01:36PM Nov 27th, 2020 01:36PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 26th, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 25th, 2020 08:41PM Nov 25th, 2020 08:41PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 24th, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 24th, 2020 04:14PM Nov 24th, 2020 04:14PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 23rd, 2020 12:00AM Vigilant Biosciences, Inc. 788 18.00 Open Biotechnology Nov 23rd, 2020 06:04PM Nov 23rd, 2020 06:04PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services
private:vigilantbiosciences 9016939 Nov 22nd, 2020 12:00AM Vigilant Biosciences, Inc. 787 18.00 Open Biotechnology Nov 22nd, 2020 04:59PM Nov 22nd, 2020 04:59PM Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical Open Biotechnology, Oncology, Diagnostics Open 500 W Cypress Creek Rd, Suite 300 Ft. Lauderdale FL US 33309 Vigilant Biosciences Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.